Clinical Trial Update: GOAL: GA101 Plus Pixantrone for Relapsed Aggressive Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial update for GOAL: GA101 plus pixantrone in relapsed aggressive lymphoma (non-Hodgkin lymphoma).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• GA101 (obinutuzumab)
• Pixantrone (pixantrone)

Snippet

Sponsor: Johannes Gutenberg University Mainz | Conditions: Lymphoma, Non-Hodgkin | Phase 2 | Status: COMPLETED